WARNING: FETAL TOXICITY When pregnancy is detected, discontinue telmisartan tablets as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue telmisartan tablets as soon as possible (5.1, 8.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1, 8.1)
Use: Labeled indications
- Treatment of hypertension, to lower blood pressure.
- Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Telmisartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors (1.2) 1.1 Hypertension Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan tablets may be used alone or in combination with other antihypertensive agents [see Clinical Studies (14.1)]. 1.2 Cardiovascular Risk Reduction Telmisartan tablets are indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.
High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage [see Clinical Studies (14.2)]. Telmisartan tablets can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy) [see Clinical Studies (14.2)].
Studies of telmisartan in this setting do not exclude the possibility that telmisartan may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves.
Use of telmisartan with an ACE inhibitor is not recommended [see Warnings and Precautions (5.6)].
Contraindications
4 CONTRAINDICATIONS Telmisartan tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product [see Adverse Reactions (6.2)]. Do not co-administer aliskiren with telmisartan in patients with diabetes [see Drug Interactions (7)]. Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product (4) Do not co-administer aliskiren with telmisartan in patients with diabetes (4)
US FDA labelDosing: Adult
- May be administered with or without food (2.1)
- When used for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary (2.2)
- Indication Starting Dose Dose Range Hypertension (2.1)
- 40 mg once daily 40 to 80 mg once daily Cardiovascular Risk Reduction (2.2)
- 80 mg once daily 80 mg once daily
2.1 Hypertension
2.1 Hypertension Dosage must be individualized. The usual starting dose of telmisartan tablets is 40 mg orally once a day. Blood pressure response is dose-related over the range of 20 to 80 mg [see Clinical Studies (14.1)]. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored. Telmisartan tablets may be administered with other antihypertensive agents. Telmisartan tablets may be administered with or without food.
2.2 Cardiovascular Risk Reduction
2.2 Cardiovascular Risk Reduction The recommended dose of telmisartan tablets are 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality. When initiating telmisartan tablets therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
Dosing: Altered kidney function
Renal Insufficiency No dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.5) and Dosage and Administration (2.1)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Insufficiency Monitor carefully and uptitrate slowly in patients with biliary obstructive disorders or hepatic insufficiency [see Warnings and Precautions (5.4)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established [see Clinical Pharmacology (12.3)]. Neonates with a history of in utero exposure to telmisartan If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of patients receiving telmisartan in hypertension clinical studies, 551 (19%) were 65 to 74 years of age and 130 (4%) were 75 years or older. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Of the total number of patients receiving telmisartan tablets in the cardiovascular risk reduction study (ONTARGET), the percentage of patients ≥65 to <75 years of age was 42%; 15% of patients were ≥75 years old. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Dosage forms
Philippines
- Tablet: 20 mg, 40 mg, 80 mg
- Film-coated tablet: 20 mg, 40 mg, 80 mg
Registered products in the Philippines
295 products registered with the Food and Drug Administration (FDA) Philippines list Telmisartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products295
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Actarb 40Telmisartan | 40 mg TabletStore at temperatures not exceeding 30°C | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-12828 | Jun 4, 2030 | |
Actarb 80Telmisartan | 80 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Village Ganguwala, Paonta Sahib, District Sirmour, Himachal Prasdesh 173025, IndiaIndia | Sun Pharma Philippines, Inc. | DRP-12827 | Jun 4, 2030 | |
AjesartTelmisartan | 80 mg TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Actavis Ltd.Malta | AJ Research & Pharma, Inc.Importer: AJ Research & Pharma | DR-XY47894 | Apr 4, 2027 | |
AmilozartTelmisartan | 40 mg TabletAlu/Alu Blister Pack x l0's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-01 | Jul 11, 2030 | |
Amisar 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | St. Raphael's Healing Ventures Incorporated doing business under the name/s and style/s of The Healers' Pharmaceutical and Medical Supplies DistributorshipImporter: Orange Biotec Inc. | DRP-3212-10 | Aug 24, 2029 | |
ARBTelmisartan | 40 mg Film-Coated TabletAluminum Strip Pack x 10's (Box of 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Iberica Verheilen Pharmaceuticals Group Corp.Importer: Verheilen Iberica Health Care Company, Inc.Trader: Farma Iberica SL | DRP-14837 | Jan 19, 2029 | |
ARB DSTelmisartan | 80 mg Film-Coated TabletAluminum Strip Pack x 10's (Box of 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Iberica Verheilen Pharmaceuticals Group Corp.Importer: Verheilen Iberica Health Care Company Inc.Trader: Farma Iberica S.L. | DR-XY47064 | Sep 21, 2030 | |
Arbitel -40Telmisartan | 40 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49723 | May 18, 2032 | |
Arbitel-80Telmisartan | 80 mg TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49722 | May 18, 2032 | |
BeisartanTelmisartan | 40 mg TabletAlu/Alu blister pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-15838 | Sep 20, 2029 | |
BeisartanTelmisartan | 80 mg TabletAlu/Alu blister pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-15839 | Sep 20, 2029 | |
CardetresTelmisartan | 40 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer's Lab (Unit II)India | NAB Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-5421-13 | Aug 5, 2029 | |
CardimisTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-16792 | Jul 11, 2030 | |
Cardiozart-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Orange Biotec Inc. | DRP-3212-04 | Aug 24, 2029 | |
Cardiozart-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Orange Biotec Inc. | DRP-3207-02 | Aug 24, 2029 | |
CardizarTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Corbridge Group Phils., Inc.Importer: Orange Biotec Inc. | DRP-3212-05 | Aug 24, 2029 | |
CorzapTelmisartan | 40 mg TabletAlu (PVC/Alu/OPA)/ Alu Blister Pack of 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Helande Kidney Care Inc.Importer: AMB HK Enterprises Inc. | DRP-10475-07 | Sep 30, 2031 | |
CorzapTelmisartan | 80 mg TabletAlu (PVC/Alu/OPA)/ Alu Blister Pack of 10’s Box of 30’s and 100’s | RxVAT-exempt | Globela Pharma Private LimitedIndia | Helande Kidney Care Inc.Importer: AMB HK Enterprises Inc. | DRP-10476-06 | Sep 30, 2031 | |
CuratelTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab Unit IIIndia | Curasave PharmaImporter: Pharmakon Biotec Inc. | DRP-5421-11 | Aug 5, 2029 | |
EdzarTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's And 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-18308 | Jun 16, 2031 | |
Emzart 40Telmisartan | 40 mg TabletAlu (PVC/Alu/OPA)/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc | DRP-10475-08 | Sep 30, 2031 | |
Emzart 80Telmisartan | 80 mg TabletAlu (PVC/Alu/OPA)/ Alu Blister Pack of 10’s Box of 30’s | RxVAT-exempt | Globela Pharma Private LimitedIndia | Emcure Pharma Philippines Inc.Importer: AMB HK Enterprises Inc. | DRP-10476-07 | Sep 30, 2031 | |
Estellar 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, IncPhilippines | Trader: Justright Healthcare Inc | DR-XY49735 | May 25, 2031 | |
Estellar 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, IncPhilippines | Trader: Justright Healthcare Inc | DR-XY49733 | May 25, 2031 | |
Glo-Sartan 40Telmisartan | 40 mg Film-coated TabletAlu-PVC Blister Pack of 14’s in a polyester/aluminum/polyethylene bag Alu-PVC Blister Pack of 10’s in a polyester/aluminum/polyethylene bag (Box of 28’s and 30’s) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-17052-01 | Sep 15, 2030 | |
Glo-Sartan 80Telmisartan | 80 mg Film-coated TabletAlu/PVC Blister Pack x 10's in a Polyester/Aluminum/Polyethylene Bag (Box of 30’s) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | PhilRx Pharma, Inc.Importer: AMB HK Enterprises, Inc. | DRP-17053-01 | Sep 15, 2030 | |
Glosartan 40Telmisartan | 40 mg TabletAlu (PVC/Alu/OPA)/Alu Blister Pack of 10's (Box of 30's); Alu (PVC/Alu/OPA)/Alu Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-10475 | Sep 30, 2031 | |
Glosartan 80Telmisartan | 80 mg TabletAlu (PVC/Alu/OPA)/Alu Blister Pack of 10's | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc. | DRP-10476 | Sep 26, 2031 | |
HardisTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals Inc. | DRP-11041-04 | Jan 12, 2027 | |
HardisTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals Inc. | DRP-11040-04 | Jan 12, 2027 | |
JestsartanTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Boon Pharma CorpImporter: Orange Biotec Inc. | DRP-3212-18 | Aug 24, 2029 | |
MabisarTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Medconcern Drugs and General Merchandise Inc.Importer: Orange Biotec Inc. | DRP-3212-12 | Aug 24, 2029 | |
Macsart 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and and 100's) | RxVAT-exempt | Macleods Pharmaceuticals Limited.India | Genedrift Philippines OPC | DRP-15386 | Jul 1, 2029 | |
Macsart 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-15385 | Jul 1, 2029 | |
MaxitelTelmisartan | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-12870 | Dec 14, 2027 | |
MaxitelTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-14304 | Aug 16, 2028 | |
MeritTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Unilab, Inc.Importer: Ritemed Phils., Inc. | DRP-11048-01 | Jan 19, 2027 | |
MeritTelmisartan | 40 mg TabletAlu-Alu/OPA/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Krka, d.d., Novo mestoSlovenia | UNILAB, Inc. | DRP-12707 | Sep 27, 2027 | |
MeritTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Unilab, Inc.Importer: Ambica International Corporation | DRP-4789-02 | Oct 4, 2028 | |
MeritTelmisartan | 40 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8339-03 | May 7, 2029 | |
MeritTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | UNILAB, INC.Importer: Ritemed Phils., Inc. | DRP-11047-01 | Jan 19, 2027 | |
MeritTelmisartan | 80 mg TabletAlu-Alu/OPA/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Krka, d. d., Novo mestoSlovenia | UNILAB, Inc. | DRP-12703 | Sep 27, 2027 | |
MeritTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Unilab, Inc.Importer: Ambica International Corporation | DRP-4790-02 | Oct 4, 2028 | |
MeritTelmisartan | 80mg TabletAlu-Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8338-03 | May 7, 2029 | |
Mevo 40Telmisartan | 40 mg TabletAlu (PVC/Alu/OPA)/ Alu Blister Pack of 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | FSPC Pharmaceuticals, Inc.Importer: AMB HK Enterprises Inc. | DRP-10475-01 | Sep 30, 2031 | |
Mevo 80Telmisartan | 80 mg TabletAlu (PVC/Alu/OPA)/ Alu Blister Pack of 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-10476-03 | Sep 30, 2031 | |
Mezartel-20Telmisartan | 20 mg Film Coated TabletAlu-Alu Blister Pack x 10's and Box of 100's (Box of 1) | RxVAT-exempt | Macter International Ltd.Pakistan | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-10270-01 | Jan 20, 2032 | |
Mezartel-40Telmisartan | 40 mg Film Coated TabletAlu/Alu Blister pack x 10's Box of10's and Box of 100's | RxVAT-exempt | Macter International LtdF-S.I.T.E Karachi 75700 Pakistan | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DR-12323-01 | Jun 30, 2031 | |
Mezartel-80Telmisartan | 80 mg Film-Coated TabletAlu-Alu blister pack x 10's and 100's (Box of 10's and Box of 100's) | RxVAT-exempt | Macter International Ltd.Pakistan | Amson PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-10266-01 | Dec 1, 2030 | |
MicardisTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Pharma GmbH & Co. KGGermany | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7825 | Oct 30, 2027 | |
MicardisTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 7's (Box of 7's) (as Physician's Sample) | RxVAT-exempt | Boehringer Ingelheim Hellas Single Member S.A.Greece | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-9597 | Mar 17, 2031 | |
MicardisTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Boehringer Ingelheim Pharma GmbH & Co. KGGermany | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7826 | Oct 4, 2027 | |
MicardisTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Hellas Single Member S.A.Greece | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-9596 | Mar 17, 2031 | |
MicargenTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-09 | Aug 5, 2029 | |
MicargenTelmisartan | 40mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Alternative Platform Exchange, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8339-05 | May 7, 2029 | |
MicarmedTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Pelltech Health Care Private LTD.India | Dreamax IncorporatedTrader: Medior Healthcare Pvt. Ltd. | DRP-18989 | Oct 14, 2031 | |
MicasTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Rule Med Pharma Corp.Importer: Orange Biotec Inc. | DRP-3212-17 | Aug 24, 2029 | |
Micavid 40Telmisartan | 40 mg TabletOPA/Alu/PVC Blister x 10's Box of 30's | RxVAT-exempt | Jubilant Generics LimitedIndia | Hovid Inc.Trader: Hovid Bhd. | DR-XY46681 | Aug 19, 2029 | |
Micavid 80Telmisartan | 80 mg TabletOPA/Alu/PVC Blister x l0's (Box of30's) | RxVAT-exempt | Jubilant Generics LimitedIndia | Hovid Inc.Trader: Hovid Bhd. | DR-XY46680 | Aug 19, 2029 | |
MicorTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | Pharmakon Biotec Inc. | DRP-5421 | Aug 5, 2029 | |
MisarTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Orange Biotec Inc. | DRP-3212 | Aug 24, 2029 | |
MisarTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Orange Biotec Inc. | DRP-3207 | Aug 24, 2029 | |
MisartTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | East African (India) OverseasIndia | Airlife International Trading Corporation.Importer: Airlife International Trading Corporation | DRP-15376 | Jun 28, 2029 | |
Misartan 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-11041-00 | Jan 12, 2027 | |
Misartan 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc.Trader: Â | DRP-11041-01 | Jan 12, 2027 | |
Misartan 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | BRP-260971-01 | Jan 12, 2027 | |
Misartan 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-11040-01 | Jan 12, 2027 | |
Misarven 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Healol Pharma Corporation | DRP-14585 | Oct 19, 2028 | |
Mistacor 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s); Alu/Alu Blister Pack x 10’s (Box of 30’s as Physician’s Sample); Alu/Alu Blister Pack x 10’s (Box of 2’s, 5’s and 10’s as Physician’s Sample) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm, Inc.Importer: Ambica International Corporation | DRP-3687-06 | May 3, 2032 | |
Mistacor 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10’s); Alu/Alu Blister Pack x 10’s (Box of 2’s, 5’s & 10’s as Physician’s Sample) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-3710-05 | Mar 29, 2032 | |
MistelTelmisartan | 40 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Nucare Labs LLP.India | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-16140 | Nov 12, 2029 | |
MistelTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | ECE Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-01 | Aug 5, 2029 | |
MistelTelmisartan | 80 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Nucare Labs LLPIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-16103 | Oct 31, 2029 | |
MizarTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DRP-6742-02 | Mar 23, 2030 | |
Mycartan-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | AMEDIQO PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8339-01 | May 7, 2029 | |
Mycartan-80Telmisartan | 80 mg TabletAlu-Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | AMEDIQO PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8338-02 | May 7, 2029 | |
Myzart 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Neo Care Philippines, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8339-07 | May 7, 2029 | |
N-Blood 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4789-01 | Oct 4, 2028 | |
N-Blood 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4790-01 | Oct 4, 2028 | |
Neo-SarTelmisartan. | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The Acme Laboratories LimitedBangladesh | Sea-King Pharma Inc. | DR-XY49412 | Jun 3, 2030 | |
Neo-SarTelmisartan | 40 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-17531 | Jun 3, 2030 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DR-XY44116 | Jan 23, 2030 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Bansan Pharma DistributorImporter: Philgen Pharmaceuticals Inc. | DRP-11041-05 | Jan 12, 2027 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-11041-3 | Jan 12, 2027 | |
NoneTelmisartan | 40 mg TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-11533 | Jun 5, 2031 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | St. Joseph DrugstoreTrader: Solvang Pharmaceuticals, Inc. | DRP-14379-01 | Aug 31, 2028 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | South Star DrugTrader: Dr. Zen's Research, Inc. | DRP-14388-01 | Aug 31, 2028 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-11 | Jul 11, 2030 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-3687-10 | May 3, 2027 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.India | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-4765-08 | Sep 30, 2028 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | Zydus Healthcare Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-10 | Aug 5, 2029 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-6176 | Jan 23, 2030 | |
NoneTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-6364-01 | Oct 2, 2030 | |
NoneTelmisartan | 40 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8339 | May 7, 2029 | |
NoneTelmisartan | 40mg TabletTriple Laminated cold form Alu/Alu Blsiter Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (Unit VII)India | Medethix, Inc. | DRP-13448 | Feb 22, 2031 | |
NoneTelmisartan | 80 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 10's, 30’s and 100's) | RxVAT-exempt | Macter International Ltd.Pakistan | Watsons Personal Care Stores (Philippines), Inc.Importer: Sahar International Trading Inc. | DRP-10266-02 | Dec 1, 2030 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DR-XY44348 | Mar 19, 2030 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals, Inc. | DRP-11040-03 | Jan 12, 2027 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Bansan Pharma DistributorImporter: Philgen Pharmaceuticals Inc. | DRP-11040-05 | Jan 12, 2027 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | South Star DrugTrader: Dr. Zen's Research, Inc. | DRP-14387-01 | Aug 31, 2028 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3’s x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-4762-08 | Sep 30, 2028 | |
NoneTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 28's, 30's and 100's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8338 | May 7, 2029 | |
NormitechTelmisartan | 40 mg TabletAlu/ (CPV / Alu/ OPA)/ Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | SNV Biotech Medicinal Products WholesalingImporter: AMB HK Enterprises Inc. | DRP-13017-01 | Nov 17, 2027 | |
NovazartTelmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Saludcare (I) Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-16225 | Sep 19, 2029 | |
OnmarcTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Ellebasy Medicale Group Inc.Importer: Orange Biotec Inc. | DRP-3212-08 | Aug 24, 2029 | |
OnmarcTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Ellebasy Medicale Group Inc.Importer: Orange Biotec Inc. | DRP-3207-06 | Aug 24, 2029 | |
OP-TelmisTelmisartan | 40 mg TabletAlu/(PVC/Alu/OPA)/Alu Blister Pack of 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Orient Pearl Med Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-10475-05 | Sep 30, 2031 | |
OP-TELMISTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 30's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Orient Pearl Med Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-4762-12 | Sep 30, 2028 | |
Oppisartan-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Orientphil Pharma Inc.Importer: Ambica International Corporation | DRP-3687-07 | May 3, 2032 | |
Oppisartan-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Orientphil Pharma Inc.Importer: Ambica International Corporation | DRP-3710-06 | Mar 29, 2032 | |
Oratel-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Suhitas Pharmaceuticals Inc.Importer: Orange Biotec Inc. | DRP-3212-07 | Aug 24, 2029 | |
Oratel-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Suhitas Pharmaceuticals Inc.Importer: Orange Biotec Inc. | DRP-3207-05 | Aug 24, 2029 | |
Retaguard 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Reta DrugImporter: Orange Biotec Inc. | DRP-3212-13 | Aug 24, 2029 | |
Retaguard 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Reta DrugImporter: Orange Biotec Inc. | DRP-3207-10 | Aug 24, 2029 | |
RhandesartanTelmisartan | 40 mg TabletAlu/PVC Blister Pack x 14’s in a Polyester/Aluminum/ Polyethylene Bag (Box of 28’s) Alu/PVC Blister Pack x 10’s in a Polyester/Aluminum/ Polyethylene Bag (Box of 30’s) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17052 | Sep 15, 2030 | |
RhandesartanTelmisartan | 80 mg TabletAlu/PVC Blister Pack x 10’s in a Polyester/ Aluminum/ Polyethylene Bag (Box of 30’s) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17053 | Sep 15, 2030 | |
RhetizarTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3687-09 | May 3, 2027 | |
Saphmis-GE40Telmisartan | 40 mg Tablet | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17704 | Feb 20, 2031 | |
Saphmis-GE80Telmisartan | 80 mg Tablet | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17703 | Feb 20, 2031 | |
T-SartanTelmisartan | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | AGB Pharmaceutical Trading and Consultancy Corporation | DRP-4708 | Sep 12, 2028 | |
T-SartanTelmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 7’s (Box of 14’s and 28’s) | RxVAT-exempt | Maple Pharmaceuticals Pvt. Ltd.Pakistan | Medlink Pharma Phils., Inc.Importer: AGB Pharmaceutical Trading and Consultancy Corporation | DRP-9708 | May 11, 2031 | |
T-SartanTelmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | AGB Pharmaceutical Trading and Consultancy Corporation | DRP-4558 | Jul 24, 2028 | |
Tartan 40Telmisartan | 40mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | Macropharma Corporation | DRP-13954 | May 25, 2028 | |
Tartan 80Telmisartan | 80mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Agio Pharmaceuticals Ltd.India | Macropharma Corporation | DRP-13953 | May 25, 2028 | |
TelarbTelmisartan | 40 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Pharmakon Biotec Inc. | DRP-4765-07 | Sep 30, 2028 | |
TelarbTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | The Cathay YSS Distributors Co., Inc.Importer: Pharmakon Biotec Inc. | DRP-4762-06 | Sep 30, 2028 | |
TelatrazTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alembic Pharmaceuticals LimitedIndia | Natrapharm Inc | DR-XY478942 | Nov 29, 2028 | |
TelatrazTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alembic Pharmaceuticals LimitedIndia | Natrapharm Inc. | DR-XY48941 | Nov 29, 2028 | |
Telbip 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | K Pharma Medical Corp.Importer: Medinova Pharmaceutical Inc. | DRP-8339-04 | May 7, 2029 | |
Telcor 40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blsiter Pack x 10's (Box of 30's) (Box of 100's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-9390-08 | Mar 2, 2031 | |
Telcor 80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-9391-05 | Mar 2, 2031 | |
Telday-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY42004 | May 6, 2028 | |
Telday-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines Inc | DR-XY42005 | May 6, 2028 | |
TeldraTelmisartan | 40 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP–15838-01 | Sep 20, 2029 | |
TeldraTelmisartan | 80 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-15839-01 | Sep 20, 2029 | |
Telfocus 40Telmisartan | 40 mg TabletTriple Laminated Cold Form Alu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (Unit VII)India | Medethix, Inc. | DRP-13447 | Feb 22, 2031 | |
Telfocus 80Telmisartan | 80 mg TabletTriple Laminated Cold Form Alu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (UNIT VII)India | Medethix, Inc. | DRP-11184 | Feb 16, 2032 | |
Telfort 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | PH Phil Asia Medica Co.Importer: Pharmakon Biotec Inc. | DRP-16792-13 | Jul 11, 2030 | |
Telfort 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | PH Phil Asia Medica Co.Importer: Pharmakon Biotec Inc. | DRP-4762-13 | Sep 30, 2028 | |
TelgioTelmisartan | 40 mg TabletOPA/Aluminum/PVC Blister pack x 10's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-12205 | Jul 1, 2027 | |
TelgioTelmisartan | 80 mg TabletOPA/Aluminum/PVC Blister pack x 10's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DRP-12206 | Jul 1, 2027 | |
TelgipTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The Acme Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DR-XY49365 | Apr 4, 2030 | |
TelgipTelmisartan | 80 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Philippines, Inc. | DRP-17530 | Apr 4, 2030 | |
Telgrand-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc. | DRP-16792-02 | Jul 11, 2030 | |
TelguardTelmisartan | 20 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Indchemie Health Specialties Private LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-18376 | Jun 24, 2031 | |
TelguardTelmisartan | 40 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Indchemie Health Specialties Private LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-18375 | Jun 24, 2031 | |
TelguardTelmisartan | 80 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Indchemie Health Specialties Private LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-18374 | Jun 24, 2031 | |
Teli 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Macropharma CorporationImporter: Ambica International Corporation | DRP-4789 | Oct 4, 2028 | |
Teli 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Macropharma CorporationImporter: Ambica International Corporation | DRP-4790 | Oct 4, 2028 | |
TeliDril 20Telmisartan | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-14386 | Aug 31, 2028 | |
TeliDril 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-14385 | Aug 31, 2028 | |
Telidril 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals Inc. | DRP-14384 | Aug 31, 2028 | |
TeliGen-20Telmisartan | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-14383 | Aug 31, 2028 | |
TeliGen-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-14382 | Aug 31, 2028 | |
TeliGen-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-14381 | Aug 31, 2028 | |
Telimac 40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) (Box of 100's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-9390-10 | Mar 2, 2031 | |
Telimac 80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-9391-07 | Mar 2, 2031 | |
Telisan 40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Prohansen Pharma Phils. Inc.Importer: Hillcross Prime, Inc. | DRP-9390-04 | Mar 2, 2031 | |
Telisan 80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Prohansen Pharma Phils.Importer: Hillcross Prime, Inc. | DRP-9391-02 | Mar 2, 2031 | |
TelisolvTelmisartan | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals. Inc. | DRP-14380 | Aug 31, 2028 | |
TelisolvTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-14379 | Aug 31, 2028 | |
TelisolvTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-14378 | Aug 31, 2028 | |
TelmanTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Littman Drug CorporationImporter: Orange Biotec Inc. | DRP-3212-09 | Aug 24, 2029 | |
TelmanTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Littman Drug CorporationImporter: Orange Biotec Inc. | DRP-3207-08 | Aug 24, 2029 | |
TelmaxTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug Corporation | DRP-6176-03 | Jan 23, 2030 | |
TelmaxTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug Corporation | DRP-6742-04 | Mar 23, 2030 | |
Telmaxa-80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 100' and 30's) | RxVAT-exempt | Saludcare (I) Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16225-01 | Dec 19, 2029 | |
TelmefixxTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-3687-04 | May 3, 2032 | |
TelmezTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47616 | Dec 20, 2026 | |
TelmezTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DRP-11522 | Dec 20, 2031 | |
TelmezTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47615 | Dec 20, 2026 | |
TelmezTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DRP-11524 | Dec 20, 2031 | |
TelmibetTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc. | DRP-3212-06 | Aug 24, 2029 | |
TelmibetTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc. | DRP-3207-03 | Aug 24, 2029 | |
Telmicard-20Telmisartan | 20 mg TabletAlu/ Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Zim Laboratories Ltd.India | Ambicare Pharmaceuticals Inc.Trader: Rainbow Life Sciences Pvt. Ltd. | DRP-5869 | Feb 17, 2032 | |
Telmicard-40Telmisartan | 40 mg TabletAlu/ Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Zim Laboratories Ltd.India | Ambicare Pharmaceuticals Inc.Trader: Rainbow Life Sciences Pvt. Ltd. | DRP-5867 | Mar 19, 2032 | |
TelmicassTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc. | DRP-8339-06 | May 7, 2029 | |
TelmicorTelmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Mars Therapeutics & Chemicals Ltd.India | Hillcross Prime, Inc. | DRP-9390 | Mar 2, 2031 | |
TelmicorTelmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Hillcross Prime, Inc. | DRP-9391 | Mar 2, 2031 | |
Telmicura 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | RVM Pharma & Medical Supplies DistributionImporter: Orange Biotec Inc. | DRP-3212-15 | Aug 24, 2029 | |
Telmicura 80Telmisartan | 80 mg TabletAlu / Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | RVM Pharma & Medical Supplies DistributionImporter: Orange Biotec Inc. | DRP-3207-11 | Aug 24, 2029 | |
Telmidec-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | HLM Pharmaceutical Inc.Importer: Orange Biotec Inc. | DRP-3212-03 | Aug 24, 2029 | |
Telmidec-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | HLM Pharmaceutical Inc.Importer: Orange Biotec Inc. | DRP-3207-07 | Aug 24, 2029 | |
TelmidinTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation | DRP-3687-05 | May 3, 2027 | |
TelmidinTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation | DRP-3710-04 | Mar 29, 2032 | |
Telmidis-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-06 | Aug 5, 2029 | |
Telmidiv - 80Telmisartan | 80mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Protech Biosystems Pvt. Ltd.India | Divjot Enterprises Corp. | DR-XY49831 | Oct 27, 2031 | |
Telmiem 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc. | DRP-18114 | May 7, 2028 | |
Telmiem 80Telmisartan | 80mg TabletAlu/Alu Blister x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-18112 | May 6, 2031 | |
TelmierraTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Sierra Pharmaceutical CorporationImporter: Orange Biotec Inc. | DRP-3212-11 | Aug 24, 2029 | |
TelmierraTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Sierra Pharmaceutical CorporationImporter: Orange Biotec Inc. | DRP-3207-09 | Aug 24, 2029 | |
Telmifast 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Healer's Lab Unit IIIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-14 | Aug 5, 2029 | |
Telmiflex-40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17419 | Jan 19, 2032 | |
Telmiflex-80Telmisartan | 80 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17170 | Oct 10, 2031 | |
TelmigenTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. LtdIndia | MeedPharma Medical Supplies and Equipment DistributorImporter: Philgen Pharmaceuticals Inc. | DRP-11041-06 | Jan 12, 2027 | |
TelmigetTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Getz Pharma (Phils.), Inc. | DRP-6176-02 | Jan 23, 2030 | |
TelmigetTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Getz Pharma (Phils.), Inc. | DRP-6742-03 | Mar 23, 2030 | |
Telmignan-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-6364 | Oct 2, 2030 | |
Telmiheart 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-3687-03 | May 3, 2032 | |
Telmiheart 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 10’s and 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-3710-02 | Mar 29, 2032 | |
TelmijazTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Jazmark PharmaceuticalImporter: Orange Biotec Inc. | DRP-3212-19 | Aug 24, 2029 | |
TelmijazTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Jazmark PharmaceuticalImporter: Orange Biotec Inc. | DRP-3207-12 | Aug 24, 2029 | |
Telminex-40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | D'Conner PharmaImporter: Hillcross Prime, Inc. | DRP-9390-06 | Mar 2, 2031 | |
Telminex-80Telmisartan | Film-Coated Tablet 80 mgAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | D'Conner PharmaImporter: Hillcross Prime, Inc. | DRP-9391-04 | Mar 2, 2031 | |
Telminorm-80Telmisartan | 80 mg TabletBlister Pack x 10's (Box of 30's) | RxVAT-exempt | Ipca Laboratories Ltd.India | Blue Global (FZE) | DRP-13106 | Dec 1, 2027 | |
Telminow 40Telmisartan | 40mg TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Cubit Lifesciences LLPIndia | Aglobal Care, Inc. | DRP-18686 | Aug 24, 2031 | |
Telminow 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cubit Lifesciences LLPIndia | Aglobal Care, Inc. | DRP-15788 | Sep 12, 2029 | |
TelmiphilTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's) | RxVAT-exempt | Zim Laboratories Ltd.India | Phil Asia Pharma Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Rainbow Life Sciences Pvt. Ltd. | DRP-5867-01 | Mar 19, 2032 | |
TelmiraTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer’s Lab. Unit IIIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-05 | Aug 5, 2029 | |
TelmirichTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Medirich Pharma Distribution Corp.Importer: Orange Biotec Inc. | DRP-3212-16 | Aug 24, 2029 | |
Telmiride-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Unison Pharmaceuticals Pvt. Ltd.India | Macropharma Corporation | DRP-16886 | Aug 8, 2030 | |
Telmiride-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Unison Pharmaceuticals Pvt. Ltd.India | Macropharma Corporation | DRP-16885 | Aug 8, 2030 | |
Telmirin 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Corbridge Group Phils., Inc.Importer: Orange Biotec Inc. | DRP-3207-04 | Aug 24, 2029 | |
Telmirx 40Telmisartan | 40mg TabletAlu/ (PVC/Alu/OPA)/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-13017 | Nov 17, 2027 | |
TELMISAPH-40Telmisartan | 40 mg TabletAlu/Alu PVC Blister x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Nelpa Lifesciences, Inc. | DRP-9616 | Mar 25, 2031 | |
Telmisaph-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Nelpa Lifesciences, Inc. | DRP-9615 | Mar 25, 2031 | |
TelmisarTelmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Euroasia Pharmaceuticals, IncTrader: Tunic Healthcare | DRP-10115 | Jun 17, 2030 | |
Telmisar 80Telmisartan | 80 mg film-coated tabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Euroasia Pharmaceuticals Inc.Trader: Tunic Healthcare | DRP-10113 | Feb 26, 2031 | |
TelmispecTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Pharmaspec N.A., Inc. | DRP-6176-04 | Jan 23, 2030 | |
Telmistal-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s); Alu/Alu Blister Pack x 10’s (Box of 2's, 5's and 10's as Physician's Sample) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-3687 | May 3, 2032 | |
Telmistal-80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 10’s, 30’s and 100’s); Alu/Alu Blister Pack x 10's (Box of 2’s, 5’s and 10’s as Physician Sample) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-3710 | Mar 29, 2032 | |
Telmitar 40Telmisartan | 40 mg TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-10423 | Oct 25, 2031 | |
Telmitar 80Telmisartan | 80 mg TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-10424 | Oct 25, 2031 | |
TelmitimeTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Rx Time Pharma CorporationImporter: Orange Biotec Inc. | DRP-3212-14 | Aug 24, 2029 | |
TelmivascTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-04 | Jul 11, 2030 | |
Telmiver-40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack X 10'S (Box Of 30'S And Box Of 100'S) | RxVAT-exempt | Kausik Therapeutics (P) Ltd.India | Brel Pharmaceutical Inc. | DRP-19104 | Oct 28, 2031 | |
Telmiver-80Telmisartan | 80 mg Film-Coated TabletAlu-Alu Blister Pack X 10'S (Box Of 30'S And Box Of 100'S) | RxVAT-exempt | Kausik Therapeutics (P) Ltd.India | Brel Pharmaceutical Inc | DRP-19105 | Oct 28, 2031 | |
TelmixedTelmisartan | 40 mg TabletAlu/Alu PVC Blister x 10's (Box of 30's | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-9616-04 | Mar 25, 2031 | |
TelmizartTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY48861 | Aug 31, 2028 | |
Telmizen 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-06 | Jul 11, 2030 | |
Telmyr-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-08 | Jul 11, 2030 | |
TELOD 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | S.M.H.P. Marketing & Consultancy | DRP-16782 | Jul 10, 2030 | |
Telsar 40Telmisartan | 40 mg TabletAlu/Alu Foil Strip of 10's (Box of 30's) | RxVAT-exempt | Unichem Laboratories LimitedIndia | Healol Pharma Corporation | DRP-11540 | Mar 10, 2029 | |
Telsar-80Telmisartan | 80 mg TabletAluminum Strip Foil x 10's (Box of 30's) | RxVAT-exempt | Unichem Laboratories LimitedIndia | Healol Pharma Corporation | DRP-8548 | Nov 20, 2028 | |
TelsartanTelmisartan | 40 mg TabletAluminum Foil Strip x 10's Box of 30's | RxVAT-exempt | Bal Pharma LimitedIndia | ENDURE MEDICAL, INC.Importer: SINGAPORE GENEBIO, INC. | DR-XY45378 | May 11, 2031 | |
Telsartin 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack X 10'S (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc | DR-XY48846 | Aug 14, 2028 | |
Telsartin 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY48843 | Aug 10, 2028 | |
TelsicareTelmisartan | 40 mg Film Coated TabletAlu/Alu blister Pack of 10's (Box of 100's) | RxVAT-exempt | Macter International LtdKarachi 75700 Pakistan | Medcare PharmaceuticalsImporter: Sahar International Tradining Inc. | DRP-12323-02 | Jun 30, 2036 | |
Telsicare-80Telmisartan | 80 mg Film-Coated TabletBox of 1 Alu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Macter InternationalPakistan | Medcare PharmaceuticalsImporter: Sahar International Trading Inc. | DRP-10266-03 | Dec 1, 2030 | |
Telsitan-20Telmisartan | 20mg Film-Coated TabletBox of 1 Alu-Alu Blister Pack x 10's and 100's Box of 10's; Box of 100's | RxVAT-exempt | Macter International Ltd.Pakistan | Sahar International Trading, Inc | DRP-10270 | Dec 1, 2030 | |
Telsitan-40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | RxVAT-exempt | — | Sahar International Trading Inc. | DRP-12323 | Jun 30, 2031 | |
Telsitan-80Telmisartan | 80mg Film-Coated TabletBox of 1 Alu-Alu Blister Pack x 10's and 100's Not Applicable | RxVAT-exempt | Macter International Ltd.Pakistan | Sahar International Trading, Inc. | DRP-10266 | Dec 1, 2030 | |
Telstar 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-6176-01 | Jan 23, 2030 | |
Telstar 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | GX International, Inc. | DRP-6742-01 | Mar 23, 2030 | |
TelsynTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-10 | Jul 11, 2030 | |
TeltanTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | Trader: SEA-King Pharma Inc. | DR-XY49577 | Jun 4, 2031 | |
Telvakon-40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India 174101 | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-03 | Jul 11, 2030 | |
TelvestaTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Health Care Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-09 | Jul 11, 2030 | |
Telwin 40Telmisartan | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Tazio Lifescience Inc.Importer: Hillcross Prime, Inc. | DRP-9390-02 | Mar 2, 2031 | |
Telwin 80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mars Therapeutics Private LimitedIndia | Tazio Lifescience Inc.Importer: Hillcross Prime, Inc. | DRP-9391-01 | Mar 2, 2031 | |
TelzelTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Healer’s Lab. Unit IIIndia | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-12 | Aug 24, 2029 | |
Telzyd 20Telmisartan | 20 mg TabletAlu/Alu Blister Pack x 10's Box of 30's; Alu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-8199 | Jun 8, 2031 | |
Telzyd 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Zydus Healthcare Philippines Inc.Importer: Orange Biotec Inc. | DRP-3212-02 | Aug 24, 2029 | |
Telzyd 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100’s) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-8200 | Jun 8, 2031 | |
TenomexTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-07 | Jul 11, 2030 | |
TerasartTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-16792-12 | Jul 11, 2030 | |
TerasartTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab Unit IIIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-5421-02 | Aug 5, 2029 | |
TerasartTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-4762-11 | Sep 30, 2028 | |
TerlisartanTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer's Lab Unit IIIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec, Inc. | DRP-5421-03 | Aug 5, 2029 | |
TerlisartanTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-4762-09 | Sep 30, 2028 | |
TesarTelmisartan | 40 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.India | Pharmakon Biotec Inc. | DRP-4765 | Sep 30, 2028 | |
TesarTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-4762 | Sep 30, 2028 | |
TesarmizTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3710-03 | Mar 29, 2032 | |
Tevex 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | AMN Life Pvt. Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY49387 | Apr 28, 2030 | |
Tevex 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | AMN Life Pvt. Ltd.India | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY49386 | Apr 28, 2030 | |
Tevilyst 80Telmisartan | 80 mg TabletAlu/Alu Blister pack x 10's | RxVAT-exempt | Inventia Healthcare LimitedIndia | Phagrosea Corporation | DRP-14726 | Dec 14, 2028 | |
Thelz-80Telmisartan | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14’s) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambitech Biopharmaceuticals Inc.Importer: AGB PHARMACEUTICAL TRADING AND CONSULTANCY CORPORATION | DRP-4558-01 | Jul 24, 2028 | |
Tsartan 40Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-15417 | Jul 5, 2029 | |
Tsartan 80Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-15416 | Jul 5, 2029 | |
UnbrandedTelmisartan | 40 mg Film Coated TabletAlu/Alu Blister pack of 10's [Box of 100's, 30's; and 10's] | RxVAT-exempt | Macter International Ltd.75700 Pakistan | Watsons Personal Care Stores (Philippines), IncImporter: Sahar International Trading Inc. | DRP-12323-03 | Jun 30, 2031 | |
UnbrandedTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-11041 | Jan 12, 2032 | |
UnbrandedTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rose Pharmacy, IncorporatedImporter: Ambica International Corporation | DRP-3687-08 | May 3, 2032 | |
UnbrandedTelmisartan | 40 mg TabletAlu/Alu PVC Blister x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Watsons Personal Care Stores (Philippines), Inc.Importer: Nelpa Lifesciences, Inc. | DRP-9616-01 | Mar 25, 2031 | |
UnbrandedTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-11040 | Jan 12, 2032 | |
UnbrandedTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DRP-13215 | Dec 9, 2032 | |
UnbrandedTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rose Pharmacy, IncorporatedImporter: Ambica International Corporation | DRP-3710-07 | Mar 29, 2032 | |
UnbrandedTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-6742 | Mar 23, 2030 | |
UnbrandedTelmisartan | 80mg TabletOPA/Aluminum/PVC Blister pack x 10's (Box of 30’s) | RxVAT-exempt | PT Dexa MedicaIndonesia | Actimed, Inc.Importer: Glorious Dexa Mandaya, Inc. | DRP-12206-01 | Jul 1, 2027 | |
UnbrandedTelmisartan | Tablet 80 mgAlu/Alu Blister x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Watsons Personal Care Stores (Philippines), Inc.Importer: Nelpa Lifesciences, Inc.Trader: IMT Fine Nutrition Marketing | DRP-9615-01 | Mar 25, 2031 | |
Vas8Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Healer's Lab. Unit IIIndia | Conjug8 Corp.Importer: Pharmakon Biotec Inc. | DRP-5421-07 | Aug 5, 2029 | |
Vas8Telmisartan | 80 mg TabletAlu/Alu Blister Pack of 3’s x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Conjug8 Corp.Importer: Pharmakon Biotec Inc. | DRP-4762-07 | Sep 30, 2028 | |
VicardisTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. LtdIndia | Vitalife Pharma & Medical Supply Inc.Importer: Philgen Pharmaceuticals, Inc | DRP-11041-02 | Jan 12, 2027 | |
VicardisTelmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centurion Laboratories Pvt. LtdIndia | Vitalife Pharma & Medical Supply Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-11040-02 | Jan 12, 2027 | |
XytelTelmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceutical & Distributors, Inc. | DR-XY49418 | Jun 5, 2030 | |
XytelTelmisartan | 80 mg TabletStore at temperatures not exceeding 30°C. : Alu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY49417 | Jun 5, 2030 | |
ZermisarTelmisartan | 40 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia Ltd.India | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-4765-09 | Sep 30, 2028 | |
ZermisarTelmisartan | 80 mg TabletAlu/Alu Blister Pack of 3's x 10's (Box of 30's) | RxVAT-exempt | Scott-Edil Pharmacia LimitedIndia | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-4762-10 | Sep 30, 2028 | |
(no brand name)Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Onesource Pharma Solutions, Inc. | DRP-11048 | Jan 19, 2027 | |
(no brand name)Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-14388 | Aug 31, 2028 | |
(no brand name)Telmisartan | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd | DRP-18113 | May 7, 2028 | |
(no brand name)Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY48524 | Dec 9, 2027 | |
(no brand name)Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Onesource Pharma Solutions, Inc. | DRP-11047 | Jan 19, 2027 | |
(no brand name)Telmisartan | 80 mg TabletTriple Laminated Cold Form Alu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (Unit VII)India | Medethix, Inc. | DRP-11148 | Feb 10, 2027 | |
(no brand name)Telmisartan | 80 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-14387 | Aug 31, 2028 | |
(no brand name)Telmisartan | 80mg TabletAlu/Alu Blister x 10's (Box of 30's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-18111 | May 6, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS • 20 mg, White to off white, round shaped, uncoated tablets, debossed with "CL 45" on one side and plain on other side • 40 mg, White to off white, oval shaped, uncoated tablets, debossed with "CL 46" on one side and plain on other side • 80 mg, White to off white, oval shaped, uncoated tablets, debossed with "CL 47" on one side and plain on other side Tablets: 20 mg, 40 mg, 80 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Avoid fetal or neonatal exposure (5.1)
- Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension (5.2)
- Monitor carefully in patients with impaired hepatic (5.4)
- or renal function (5.5)
- Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker (5.6)
5.1 Fetal Toxicity
5.1 Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.
When pregnancy is detected, discontinue telmisartan tablets as soon as possible [see Use in Specific Populations (8.1)].
5.2 Hypotension
5.2 Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. Either correct this condition prior to administration of telmisartan tablets, or start treatment under close medical supervision with a reduced dose.
If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.
5.3 Hyperkalemia
5.3 Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Consider periodic determinations of serum electrolytes to detect possible electrolyte imbalances, particularly in patients at risk.
5.4 Impaired Hepatic Function
5.4 Impaired Hepatic Function As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Initiate telmisartan at low doses and titrate slowly in these patients [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
5.5 Impaired Renal Function
5.5 Impaired Renal Function As a consequence of inhibiting the renin-angiotensin-aldosterone system, anticipate changes in renal function in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure or renal dysfunction), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.
Similar results have been reported with telmisartan [see Clinical Pharmacology (12.3)]. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of telmisartan in patients with unilateral or bilateral renal artery stenosis, but anticipate an effect similar to that seen with ACE inhibitors.
5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAS)
5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAS) Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months.
Patients receiving the combination of telmisartan tablets and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with groups receiving telmisartan alone or ramipril alone. In most patients no benefit has been associated with using two RAS inhibitors concomitantly.
In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on telmisartan tablets and other agents that affect the RAS. Do not co-administer aliskiren with telmisartan tablets in patients with diabetes. Avoid concomitant use of aliskiren with telmisartan tablets in patients with renal impairment (GFR <60 mL/min/1.73 m²).
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Aliskiren: Do not co-administer aliskiren with telmisartan in patients with diabetes. Avoid use of aliskiren with telmisartan in patients with renal impairment (GFR <60 mL/min). Digoxin: When telmisartan tablet was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed.
Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range. Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan.
Therefore, monitor serum lithium levels during concomitant use. Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure.
These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.
- NSAIDs: Increased risk of renal impairment and loss of anti-hypertensive effect (7)
- Do not co-administer aliskiren with telmisartan tablets in patients with diabetes (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.
Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Adverse reactions
- The following adverse reaction is described elsewhere in labeling: Renal dysfunction upon use with ramipril [see Warnings and Precautions (5.6)] Hypertension: The most common adverse events (≥1%) reported in hypertension trials are back pain, sinusitis, and diarrhea (6.1)
- Cardiovascular risk reduction: The serious adverse events (≥1%) reported in cardiovascular risk reduction trials were intermittent claudication and skin ulcer (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Hypertension Telmisartan has been evaluated for safety in more than 3700 patients, including 1900 treated for over 6 months and more than 1300 for over one year.
Adverse experiences have generally been mild and transient in nature and have infrequently required discontinuation of therapy. In placebo-controlled trials involving 1041 patients treated with various doses of telmisartan (20 to 160 mg) monotherapy for up to 12 weeks, the overall incidence of adverse events was similar to that in patients treated with placebo.
Adverse events occurring at an incidence of ≥1% in patients treated with telmisartan and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in Table 1. Table 1 Adverse Events Occurring at an Incidence of ≥1% in Patients Treated with Telmisartan and at a Greater Rate Than Patients Treated with Placebo Telmisartan n=1455 % Placebo n=380 % Upper respiratory tract infection 7 6 Back pain 3 1 Sinusitis 3 2 Diarrhea 3 2 Pharyngitis 1 0 In addition to the adverse events in the table, the following events occurred at a rate of ≥1% but were at least as frequent in the placebo group: influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, coughing, hypertension, chest pain, nausea, and peripheral edema.
Discontinuation of therapy because of adverse events was required in 2.8% of 1455 patients treated with telmisartan tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials. The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients. The incidence of cough occurring with telmisartan in 6 placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%).
In addition to those listed above, adverse events that occurred in more than 0.3% of 3500 patients treated with telmisartan monotherapy in controlled or open trials are listed below. It cannot be determined whether these events were causally related to telmisartan tablets: Autonomic Nervous System: impotence, increased sweating, flushing; Body as a Whole: allergy, fever, leg pain, malaise; Cardiovascular: palpitation, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECG; CNS: insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesia; Gastrointestinal: flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disorders; Metabolic: gout, hypercholesterolemia, diabetes mellitus; Musculoskeletal: arthritis, arthralgia, leg cramps; Psychiatric: anxiety, depression, nervousness; Resistance Mechanism: infection, fungal infection, abscess, otitis media; Respiratory: asthma, bronchitis, rhinitis, dyspnea, epistaxis; Skin: dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Vascular: cerebrovascular disorder; and Special Senses: abnormal vision, conjunctivitis, tinnitus, earache.
During initial clinical studies, a single case of angioedema was reported (among a total of 3781 patients treated). Clinical Laboratory Findings In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of telmisartan tablets. Hemoglobin: A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% telmisartan patients compared with 0.3% placebo patients.
No patients discontinued therapy because of anemia. Creatinine: A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% telmisartan patients compared with 0.3% placebo patients. One telmisartan-treated patient discontinued therapy because of increases in creatinine and blood urea nitrogen. Liver Enzymes: Occasional elevations of liver chemistries occurred in patients treated with telmisartan; all marked elevations occurred at a higher frequency with placebo.
No telmisartan-treated patients discontinued therapy because of abnormal hepatic function. Cardiovascular Risk Reduction Because common adverse reactions were well characterized in studies of telmisartan in hypertension, only adverse events leading to discontinuation and serious adverse events were recorded in subsequent studies of telmisartan for cardiovascular risk reduction.
In TRANSCEND (N=5926, 4 years and 8 months of follow-up), discontinuations for adverse events were 8.4% on telmisartan and 7.6% on placebo. The only serious adverse events at least 1% more common on telmisartan than placebo were intermittent claudication (7% vs 6%) and skin ulcer (3% vs 2%).
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of telmisartan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders: Anemia, eosinophilia, thrombocytopenia Gastrointestinal Disorders: Abdominal pain, diarrhea, dyspepsia, nausea General Disorders and Administration Site Conditions: Asthenia, chest pain, edema, face edema, fatigue, lower limb edema, pain, weakness Hepato-biliary: Abnormal hepatic function/liver disorder Immune System Disorders: Anaphylactic reaction, hypersensitivity Investigations: Increased CPK, uric acid increased Metabolism and Nutrition Disorders: Hyperkalemia, hypoglycemia (in diabetic patients), hyponatremia Musculoskeletal and Connective Tissue Disorders: Myalgia Nervous System Disorders: Dizziness, headache, syncope Renal and Urinary Disorders: Renal impairment including acute renal failure Reproductive System and Breast Disorders: Erectile dysfunction Respiratory, Thoracic and Mediastinal Disorders: Coughing Skin and Subcutaneous Tissue Disorders: Angioedema (with fatal outcome), angioneurotic edema, drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), erythema, sweating increased, urticaria Vascular Disorder: Hypotension (including postural hypotension) Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers, including telmisartan.
Adverse reaction frequency tables (US label) US FDA label
| Telmisartan n=1455 % | Placebo n=380 % | |
| Upper respiratory tract infection | 7 | 6 |
| Back pain | 3 | 1 |
| Sinusitis | 3 | 2 |
| Diarrhea | 3 | 2 |
| Pharyngitis | 1 | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Telmisartan tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Clinical Considerations).
Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Studies in rats and rabbits with telmisartan showed fetotoxicity only at maternally toxic doses (see Data).
When pregnancy is detected, discontinue telmisartan tablet as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Use of drugs that act on the RAS in the second and third trimesters of pregnancy can result in the following: oligohydramnios, reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. In patients taking telmisartan tablets during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment.
Fetal testing may be appropriate, based on the week of gestation. If oligohydramnios is observed, discontinue telmisartan tablets, unless it is considered lifesaving for the mother. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.
Closely observe infants with histories of in utero exposure to telmisartan tablets for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function [see Use in Specific Populations (8.4)].
Data Animal Data No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day. In rabbits, embryolethality associated with maternal toxicity (reduced body weight gain and food consumption) was observed at 45 mg/kg/day [about 12 times the maximum recommended human dose (MRHD) of 80 mg on a mg/m 2 basis].
In rats, maternally toxic (reduction in body weight gain and food consumption) telmisartan doses of 15 mg/kg/day (about 1.9 times the MRHD on a mg/m 2 basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain. The no-observed-effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are about 0.64 and 3.7 times, on a mg/m2 basis, the maximum recommended human dose of telmisartan (80 mg/day).
Mechanism of action
12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis.
Telmisartan has much greater affinity (>3,000 fold) for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.
Because telmisartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours. Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients.
The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).
In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.
Pharmacokinetics
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
Metabolism and Elimination Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Terminal half-life and total clearance appear to be independent of dose.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose.
The absolute bioavailability of telmisartan is dose dependent. At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20 mg to 160 mg, with greater than proportional increases of plasma concentrations (C max and AUC) with increasing doses.
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once daily dosing are about 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once daily dosing.
Distribution Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 - acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding. Metabolism and Elimination Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.
Total plasma clearance of telmisartan is >800 mL/min. Terminal half-life and total clearance appear to be independent of dose. Specific Populations Renal Insufficiency No dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.5) and Dosage and Administration (2.1)].
Hepatic Insufficiency In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)]. Gender Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males.
In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women. No dosage adjustment is necessary. Geriatric Patients The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years [see Dosage and Administration (2.1)].
Pediatric Patients Telmisartan pharmacokinetics have not been investigated in patients <18 years of age. Drug Interaction Studies Telmisartan Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C max and AUC of ramipril 2.3-and 2.1-fold, respectively, and C max and AUC of ramiprilat 2.4-and 1.5-fold, respectively.
In contrast, C max and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.
Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.
Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Telmisartan 40 mg Tablet | ₱10.00–₱16.07Reference ₱13.62 | per tablet | DPRI procurement range |
| Telmisartan 80 mg Tablet | ₱18.00–₱31.80Reference ₱25.00 | per tablet | DPRI procurement range |
| 40 mg tablet | ₱10.00 | per tablet | PhilHealth GAMOT fixed fee |
| 80 mg tablet | ₱13.75 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Telmisartan |
| PNF listing | Oral: 40 mg and 80 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Telmisartan · Redpharm Drug [US FDA-approved label, version 1, July 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5743c58e-deab-ac93-e063-6294a90ac1eb
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

